Results 191 to 200 of about 20,192 (256)

Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review. [PDF]

open access: yesBioengineering (Basel)
Kemer ÖE, Mekala P, Dave B, Kooner KS.
europepmc   +1 more source

Cardiac safety of ophthalmic timolol

Expert Opinion on Drug Safety, 2016
Introduction: It is generally believed that topical administration of eye drops safeguards against harmful systemic effects. However, about 80% of the drug in the ophthalmic products is systemically absorbed and the first-pass metabolism is avoided ...
J. Mäenpää, O. Pelkonen
semanticscholar   +4 more sources

Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film

Cutaneous and Ocular Toxicology, 2020
Purpose The objective of this study was to investigate the influence of topical preservative-free timolol, benzalkonium chloride(BAC)-preserved timolol, BAC-preserved timolol, and BAC-preserved brimonidine on total protein concentration, advanced ...
L. Sedlak   +3 more
semanticscholar   +1 more source

Timolol loaded microemulsion laden silicone contact lens to manage glaucoma: in vitro and in vivo studies

, 2020
To manage glaucoma, timolol is currently delivered via eye drop solution in high doses due to poor ocular bioavailability. The silicone contact lenses can be used to control the release of timolol by conventional soaking technology without changing or ...
Ning Wei   +3 more
semanticscholar   +1 more source

TIMOLOL MALEATE

Medical Journal of Australia, 1979
A randomized, double-masked trial of various concentrations of timolol maleate ophthalmic solution (0.1%, 0.25%, 0.5%, and 1.0%) vs placebo demonstrated that all concentrations of timolol effectively lowered intraocular pressure (IOP). A 0.5% solution of timolol was as effective in reducing IOP as the 1.0% concentration.
Michael E. Yablonski   +3 more
openaire   +5 more sources

Home - About - Disclaimer - Privacy